Here's a look at some of the top regulatory stories for medical device companies this week: JNJ continues to pay hefty integration charges on Synthes deal; Stryker: Mako sales not as strong as we hoped; ConvaTec owners appoint banks to explore sale: sources; BD buys Irish next-gen sequencing startup GenCell Biosystems; Valeant says may raise Allergan bid; beats on profit
, Becton Dickinson & Co.
, DePuy Synthes
, GenCell Biosystems
, Johnson & Johnson
, Kimberly-Clark Worldwide Inc.
, MAKO Surgical Corp.
, Stryker Corp.
, Valeant Pharmaceuticals
, 3M Corp.
, Allergan Inc.
More than 2½ years after it spent $21.3 billion on Synthes, Johnson & Johnson continues to take hefty charges on integrating the orthopedics company into its DePuy franchise.
Profits during Biomet's fiscal 1st quarter plunge 77% despite nearly across-the-board sales increases for its orthopedic implants.
Biomet today reported a 77% profit slide for its fiscal 1st quarter, despite posting sales gains across its all but 1 line of orthopedic implants.
Here's a look at some of the top regulatory stories for medical device companies this week: Medtronic, Covidien name peripherals biz transition team; Medtronic is still in on Covidien buyout; The Street cheers changes to the Medtronic, Covidien deal; Zimmer adds Harvard spinout Etex Corp.; EU to extend Zimmer, Biomet probe
European anti-trust regulators are extending their probe into the proposed $13 billion merger of orthopedics rivals Zimmer and Biomet.
UPDATED Oct. 2, 2013, with comment from Zimmer.
Zimmer and Biomet provide updates following the 2nd in a series of "Integration Summits" where company leadership is fleshing out the details of their $13 billion merger.
Leadership at Zimmer (NYSE:ZMH) and Biomet have been on merger overdrive in recent weeks, holding summits and hosting presentations as the companies navigate the tricky business of a $13 billion merger.
Here's a look at some of the top Wall Street stories for medical device companies this week: Second suitor ceded early to Zimmer in chase for Biomet; Kimberly-Clark readies Halyard Health medical device spinout; InVivo's stock drops as ex-CEO dumps shares; Mevion Medical files for $69M IPO; ReWalk Robotics prices IPO at $36M, below range